drugset / Trial / NCT05693688
Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth
Phase 4
Completed
760 enrolled
Academic Medical Center - University of Amsterdam
Amphia Hospital · collabDeventer Ziekenhuis · collabDiakonessenhuis, Utrecht · collabErasmus Medical Center · collabFlevoziekenhuis · collabFranciscus Gasthuis · collabFrisius Medisch Centrum · collabGelre Hospitals · collabGroene Hart Ziekenhuis · collabHaaglanden Medical Centre · collabIsala · collabLeiden University Medical Center · collabMaastricht University Medical Center · collabMartini Hospital Groningen · collabMaxima Medical Center · collabMedisch Spectrum Twente · collabNational Maternity Hospital, Ireland · collabNottingham University Hospitals NHS Trust · collabOLVG · collabRadboud University Medical Center · collabRijnstate Hospital · collabSpaarne Gasthuis · collabSt. Antonius Hospital · collabTergooi Hospital · collabUMC Utrecht · collabUniversity Medical Center Groningen · collabZiekenhuisgroep Twente · collabZonMw: The Netherlands Organisation for Health Research and Development · collabZuyderland Medical Centre · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to investigate if tocolysis with atosiban in late preterm birth (30 to 34 weeks) is (cost-) effective compared with placebo in improving neonatal morbidity and mortality.
Timeline
- Start
- 2017-12-01
- Primary completion
- 2024-02-29
- Completion
- 2024-02-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atosiban | Other / unclassified | 6 mg | Intravenous |
Indications
No indication recorded.